Wells Fargo’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-16,333
Closed -$759K 7770
2023
Q2
$759K Buy
16,333
+9,856
+152% +$341K ﹤0.01% 3649
2023
Q1
$186K Buy
6,477
+6,465
+53,875% +$191K ﹤0.01% 4478
2022
Q4
$374 Sell
12
-1,040
-99% -$33.9K ﹤0.01% 6465
2022
Q3
$21K Buy
1,052
+798
+314% +$14.5K ﹤0.01% 5380
2022
Q2
$4K Sell
254
-2,773
-92% -$47.7K ﹤0.01% 6136
2022
Q1
$58K Sell
3,027
-4,976
-62% -$88.8K ﹤0.01% 5582
2021
Q4
$203K Buy
+8,003
New +$235K ﹤0.01% 5262

Wells Fargo's DICE Position: Q3 2023 in Review

Wells Fargo sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 16,333 shares — an estimated $759K sold.

Wells Fargo first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $759K in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • Wells Fargo reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Wells Fargo sold 16,333 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $759K.
  • Wells Fargo first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • Wells Fargo's DICE Therapeutics, Inc. Common Stock position peaked at $759K in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.